Research Poster: Hoxb8-derived anti-GPC3 CAR expressing macrophages as a preclinical model for HCC immunotherapies

My research project involved engineering macrophages from Hoxb8 progenitors to express a GPC3-specific CAR for targeting hepatocellular carcinoma. The cells retained macrophage identity and CAR expression, offering a scalable platform to develop macrophage-based immunotherapies for HCC.